Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Through LillyDirect, patients can access Zepbound at a monthly cost of $550 for a 5mg shot, half the $1,060 list price offered to insurers before discounts or rebates and the same price someone ...

Another drug, Zepbound, also contains the same active ingredient ... Your doctor will likely have you start treatment with a 2.5-mg dose of Mounjaro. After 4 weeks of treatment, they’ll increase ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Dalteparin b 200 IU/kg s.c. once daily (or 100 IU/kg s.c. b.i.d.) 72.08 Enoxaparin 1 mg/kg s.c. b.i.d. 97.96 1.5 mg/kg s.c. once daily 73.50 Tinzaparin 175 IU/kg s.c. once daily 58.80 ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...